Goldman MP, et al. - Researchers investigated how intensive glucose control (IGC) influence the risk of lower extremity amputation (LEA) in patients with type 2 diabetes during a randomized-controlled multicenter trial. In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, patients with type 2 diabetes were randomized to IGC (HbA1c target < 6.0%) or standard glycemic control (SGC; HbA1c target 7.0% to 7.9%). Outcomes demonstrate a reduction in the risk of LEA in association with IGC. They noted that IGC had an enduring protective effect against LEA after 3.7 years. Improved glycemic control may strongly predict a decreased risk for subsequent LEA. Tight glycemic control, even over a short time period, was identified as beneficial for reducing the risk of limb loss.